Endra Life Sciences Inc. (NDRA) SEC Filing 8-K Material Event for the period ending Wednesday, February 9, 2022

Endra Life Sciences Inc.

CIK: 1681682 Ticker: NDRA

View differences made from one to another to evaluate Endra Life Sciences Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Endra Life Sciences Inc..


Assess how Endra Life Sciences Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Endra Life Sciences Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Endra Life Sciences Inc. provided additional information to their SEC Filing as exhibits

Ticker: NDRA
CIK: 1681682
Form Type: 8-K Corporate News
Accession Number: 0001654954-22-001378
Submitted to the SEC: Thu Feb 10 2022 8:00:47 AM EST
Accepted by the SEC: Thu Feb 10 2022
Period: Wednesday, February 9, 2022
Industry: Electromedical And Electrotherapeutic Apparatus
  1. Financial Exhibit
  2. Other Events
  3. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: